The understanding of disease mechanisms is advancing rapidly, leading to innovations which enable earlier and more accurate detection, diagnosis and prognostication, including ruling-out disease in those who can be safely reassured. This gives opportunities for better population health and targeted care pathways bespoke to individuals. However, there remains a critical gap between these discoveries being made in universities or businesses and implementation to local population benefit. An intervention is required to simultaneously tackle health and wealth through inclusive, innovation-led growth.
The Advanced Diagnostics Accelerator - extension will continue to do this through a series of projects looking at GM's major morbidities (liver, heart, lung, CVD) in which academic and industry excellence from our frontier sectors of advanced diagnostics and digital/data will be brought together to reimagine citizen pathways with NHS stakeholders and residents.